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Abstract
Purpose The purpose of this study was to determine the fer-
tility rates following treatment by means of the BEACOPP
regimen (regular and escalated) (bleomycin, etoposide, doxo-
rubicin, cyclophosphamide, vincristine, procarbazine, predni-
sone) as compared to the ABVD regimen (doxorubicin, vin-
blastine, dacarbazine, bleomycin) in Hodgkin lymphoma pa-
tients under the age of 40 at the time of treatment.
Methods A questionnaire was sent to 180 Hodgkin lympho-
ma (HL) patients. The questionnaire was composed of ques-
tions concerning reproduction and also menopausal and aging
symptoms in females and males. The analyses were made
using data collected from 123 patients (76 females and 47
males) who returned the questionnaire. All of the patients
were treated between 1999 and 2012.
Results In comparing the ABVD and BEACOPP groups of
female patients, the frequency of the therapy-induced amenor-
rhea and the restoredmenses following treatment were found to
be significantly different statistically (p=0.002 and p=0.012,
respectively). The secondary amenorrhea statistically appeared
more often in the BEACOPP group (p=0.003) while the cases
of achieving pregnancy and having children after chemo-
therapy were not significantly different (p=0.630, p=0.070,
respectively). In comparing the ABVD and BEACOPP treat-
ments in male patients, the only significant difference was in
the number of artificially inseminated or in vitro pregnancies
achieved in the BEACOPP and escalated BEACOPP group,
p=0.008 and p=0.002, respectively. In total, 45.2% of patients
in the ABVD female group, 34.6 % in the BEACOPP female
group, 52.6 % in the ABVD male group, and 33.3 % in the
male BEACOPP group, respectively, of patients attempting
conception post-therapy, had children after chemotherapy.
Conclusions Based on these high rates of childbirth following
BEACOPP chemotherapy, we have concluded that intensified
chemotherapy is not a definite predictor of reduced fertility in
young HL patients.
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Introduction
Hodgkin lymphoma (HL) is one of the most curable types of
lymphoma [1]. Patients are usually young when treated with
chemotherapy [2, 3], so being aware of the postliminary con-
sequences of oncologic treatment is crucial. Chemotherapy
has been linked to gonadal damage [2–5], with myeloablative
therapy increasing the likelihood of childlessness [6]. A study
by Meirow et al. on female reproductive organs showed that
premature ovarian failure is more frequent in women over
30 years of age, and that this depends on the chemotherapeutic
regimen and the particular dose of pelvic irradiation [3]. Es-
pecially toxic to the ovarian tissue are alkylating agents [2, 5,
7]. For male patients, Rueffer et al. demonstrated that 70 % of
patients suffer from disease-related gonadal dysfunction and
semen abnormality even before the initiation of treatment [8].
Today, semen analysis and cryoconservation prior to HL treat-
ment is part of the standard procedure [4, 9].
There have beenmany studies dealingwith fertility in patients
following HL treatment performed to the present day [2, 4–6,
10–12]. The dose-escalated BEACOPP (bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, and
prednisone, where the alkylating agents are cyclophosphamide
and procarbazine) regimen has been linked to a higher incidence
of secondary amenorrhea than theABVD regimen (doxorubicin,
vinblastine, dacarbazine, and bleomycin, where an alkylating
agent is dacarbazine); these two being the most frequently used
regimens [3, 4, 13]. The latest largest study by Behringer et al.
showed that hormone levels correlated with the intensity of
chemotherapy as well as the fact that survivors (following
BEACOPP treatment for advanced-stage disease) had the
highest risk of symptomatic gonadal dysfunction [13].
The aim of this study was to determine whether the
BEACOPP regimen (regular and escalated) compared to the
ABVD regimen’s reportedly low fertility rates in Hodgkin
lymphoma patients under the age of 40 at the time of treatment.
Patients and methods
Patients
The study population included 180 adult patients with HL,
who received treatment at the Institute of Oncology in Lju-
bljana between 1999 and 2012 and were also under age of
40 at the time of treatment. All of these patients were treated
with chemotherapy in form of the ABVD (mostly stages I and
II) or BEACOPP regimen (mostly stages III or IV until 2011
with 4 cycles of escalated and 4 cycles of regular BEACOPP
and, from 2012 on with 6 cycles of escalated BEACOPP).
Patients with the nodular lymphocyte predominant type of
HL, treated only with irradiation, were excluded from the
evaluation as well as patients who received other treatment
regimens, i.e., patients treated with pediatric protocols. Pa-
tients whose histological diagnosis was inconclusive were al-
so excluded. Informed consent was obtained from all individ-
ual participants included in the study and the study was ap-
proved by the national ethical committee.
Questionnaire
We designed a questionnaire including questions about how
many pregnancies patients had had before chemotherapy, how
many children they had had before chemotherapy, whether or
not their menstrual cycle was regular prior to treatment, and
whether or not it returned after treatment. Questions
concerning the number of children born and pregnancies
achieved following treatment were also included, as were
the questions regarding embryo/oocyte cryopreservation and
in vitro fertilization. For females, the questionnaire, the Men-
opausal Rating Scale (MRS) [14, 15], was translated into Slo-
vene language comprising the 11 complaints, but without
scoring every complaint individually. Patients evaluated their
total menopausal symptoms (hot flushes, sweating, unpleasant
sensation of impulsive heart palpitations, sleeping disorders, a
more depressed mood, irritability, exhaustion, bladder diffi-
culties, vaginal dryness, muscle, and joint pain) with a score
from 1 to 10. For males, questions dealing with children en-
gendered before and after chemotherapy were the same. Our
male patients were also asked to answer whether or not they
had had sperm cryopreservation and whether they had used it
for fertilization. The Aging Males’ Symptoms scale (AMS)
[16] was also translated into Slovene language scoring the
overall complaints on a scale from 1 to 10 (muscle and joint
pain, hot flushes, sleeping disorders, excessive need to sleep, a
more depressed mood, irritability, exhaustion, loss of physical
strength, diminished hair growth, fewer morning erections,
loss of sexual desire). The MRS and AMS part of the ques-
tionnaire were a subjective measure of patients’ symptoms.
In the questionnaire, questions regarding a partner’s fertil-
ity were not asked nor were questions about birth control. The
male questionnaire comprised no questions including testos-
terone treatment of any kind. However, at the end of the ques-
tionnaire, all patients were encouraged to comment on any of
the questions included as well as state whether they had had as
many children as they had wanted as well as whether they
were trying to have children post-treatment.
Determination of hormonal levels as well as gynecological
examinations to evaluate patients’ fertility status was not a
part of this study.
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Prior to sending out the questionnaire, each of the
180 patients included in the study population was called
in order to obtain her/his consent for the questionnaire.
After obtaining consent, the survey was mailed to their
address. Four weeks later, the filled in questionnaires
(signed and with informed consent) were included in a
further analysis, while the non-responders were neither
called nor resent the questionnaire. Patients were un-
compensated for participation in the study.
Statistics
The tests used for analyses included the chi-square, unpaired t
test, Pearson’s correlation test, Mann-Whitney test, and the
ANOVA test (for age correlation concerning the number of
children born before and after treatment, three subgroups were
made: 0—no children, 1—1 child, 2—two or more children).
The p value <0.05 (two-sided) was considered to be statisti-
cally significant. The programs used included the SPSS Sta-
tistics (version 19.0, IBM SPSS Inc., USA) and the GraphPad
Prism program (version 3.02, GraphPad Software, USA).
Results
Patients’ characteristics
A total of 131 (72.78 %) of the 180 patients contacted
returned a completed questionnaire. Eighty-two were fe-
male (85 % response rate), 49 were male (58 % re-
sponse rate). Following the aforementioned exclusions,
123 questionnaires were analyzed. Patients were divided
into two groups: one that received the ABVD treatment
and the other that received the BEACOPP treatment,
either regular or escalated. If the patient began with
BEACOPP and was later treated with ABVD for what-
ever reason, he or she was assigned to the BEACOPP
group. The BEACOPP group was further subdivided
into escalated and normal dosing subgroups for the pur-
pose of statistical analyses. All patients who received at
least one cycle of escalated BEACOPP were included
into the eBEACOPP subgroup.
There was no significant difference in the disease stage or
treatment of those who returned the questionnaire and those
who did not (p=0.348 and p=0.244, respectively). Patients
answered the questionnaire between 2 and 16 years after treat-
ment with a median of 9 years. The number of children
patients had before the treatment had no influence on
the selection of therapy regimen. None of the patients
were prescribed gonadotropin-releasing hormone ana-
logues during their treatment.
Female survivors
In the ABVD group, the median age at the time of treatment
was 26 years (range 18–39) (Table 1). Two (4.3 %) patients
had stage I of the disease, 39 (84.8 %) patients had stage II,
one (2.2 %) patient had stage III, and four (8.7 %) patients had
stage IV of the disease. Two (4.3 %) patients suffered from
constitutional symptoms. Nine patients (19.6 %) had bulky
disease and two (4.3 %) had extranodal involvement.
Ninety-three point five percent of patients reported a regular
menstrual cycle prior treatment. The median number of che-
motherapy cycles received was 4 (range 2–8). One (2.2 %)
patient had her pelvis irradiated with 23.4 Gy and underwent
oocyte cryopreservation prior to treatment. Six patients
(13.0 %) relapsed after first line treatment, five received sal-
vage chemotherapy, and one underwent surgical removal of
the involved lymph node. All but one, are at present in com-
plete remission (CR).
In the BEACOPP group, the median age at the time of
treatment was 26.5 years (range 20–36). Ten (33.3 %) patients
had stage II of the disease, five (16.7 %) patients had stage III,
and 15 (50.0 %) patients had stage IV of the disease. Nine
(30.0 %) had constitutional symptoms and nine (30.0 %)
had bulky disease. Seven (23.3 %) had an extranodal locali-
zation. Ninety-three point three percent of patients reported a
regular menstrual cycle prior to treatment. The median num-
ber of chemotherapy cycles received was 8 (range 4–8). There
was only one relapse (3.3 %) in this group (the patient in
question was treated with salvage chemotherapy and is now
in remission). The rest of the group achieved CR after first line
treatment with chemotherapy or chemoradiotherapy. None of
the patients received irradiation of the pelvis.
A higher age in female patients correlated significantly
with a higher number of children born before and a lower
number of children born after treatment (p<0.001, p=0.032,
respectively) (Table 2). There was no difference in age at the
time they answered the questionnaire (p=0.905). Regardless
of the regimen used, a higher age at the time of treatment also
correlated positively with therapy-induced amenorrhea as well
as with the presence of menopausal symptoms and correlated
negatively with pregnancies achieved after treatment as well
as in the birth of children after therapy (p=0.016, p<0.001,
p=0.014, p=0.010, respectively). A higher age at the time of
treatment in the ABVD group correlated only with a higher
number of children prior to the treatment (p=0.002) and also
with the presence of menopausal symptoms (p=0.013). How-
ever, in the BEACOPP group, a higher age at the time of
treatment significantly correlated with a higher number of
children born before treatment (p<0.001). A positive correla-
tion was found with therapy-induced amenorrhea and with the
presence of menopausal symptoms while a negative correla-
tion was found with both the restored menses and with the
birth of children after chemotherapy (p=0.029, p=0.015,
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p=0.010, and p=0.040, respectively). It did not correlate with
the number of achieved pregnancies (p=0.051) or with the
severity of menopausal symptoms (p=0.511). None of our
patients had been fertilized with a donor egg cell, though
one female was in the process of in vitro fertilization with a
donor egg at the time of the questionnaire. Only one patient
from the ABVD and one from the BEACOPP group reported
difficulties in becoming pregnant before chemotherapy. They
both bore one child following chemotherapy with one of them
(ABVD) selecting the in vitro fertilization procedure.
The severity of problems in achieving pregnancy before
treatment did not differ among ABVD and BEACOPP groups
nor did the embryo/oocyte cryopreservation (p=1.000, data
not shown and p=0.516 (Table 1), respectively). Only four
women in each treatment group reported that they had not
tried to conceive a child after the treatment. The therapy-
induced amenorrhea was significantly different statistically
among the groups and so was the restored menses after treat-
ment (p=0.002 and p=0.012, respectively, Tables 1 and 2).
The value of the therapy-induced amenorrhea was only deter-
mined for women who had previously had regular cycles.
There was no difference in amenorrhea and restored menses
among women below and over 30 years of age in joined group
analyses (p=0.388). Statistically, secondary amenorrhea after
treatment appeared significantly more often in the BEACOPP
group (p=0.003, Table 1 and 2) and was also more frequent in
patients over 30 years of age (p=0.008). It was defined as an
absent (and not only irregular) cycle after treatment. Achiev-
ing pregnancy (conception) and having children after chemo-
therapy were non-significant variables between the two
groups (p=0.630, p=0.070, respectively). Only one patient
in the ABVD group reported a miscarriage, but had another
child after treatment while others birthed live children. Also,
no difference was found among the groups in regard to the
Table 1 Female patients’ characteristics
ABVD group BEACOPP group p value
Number of patients 46 30 (19e/11b) NA
Median age in years at diagnosis (range) 26 (range 18–39) 26.5 (range 20–36) p= 0.869
Stage of disease prior to treatment
I 2 (4.3 %) 0 (0 %) NA
II 39 (84.8 %) 10 (33.3 %) NA
III 1 (2.2 %) 5 (16.7 %) NA
IV 4 (8.7 %) 15 (50.0 %) NA
A/B 44 (95.7 %)/2 (4.3 %) 21 (70.0 %)/9 (30.0 %) p= 0.005
X 9 (19.6 %) 9 (30.0 %) p= 0.408
E 2 (4.3 %) 7 (23.3 %) p= 0.025
Median number of cycles (range) 4 (range 2–8) 8 (range 4–8) NA
CR/PR after chemotherapy 8 (17.4 %)/38 (82.6 %) 12 (40.0 %)/18 (60.0 %) p= 0.036
Irradiation of the pelvis 1 (2.2 %) 0 (0 %) p= 1.000
Number of patients receiving at least 1 cycle of eBEACOPP 0 (0 %) 19 (63.3 %) NA
Number of patients with children before treatment 17 (37.0 %) 16 (53.3 %) p= 0.154
Regular cycle before treatment 43 (93.5 %) 28 (93.3 %) p= 1.000
Embryo/oocyte cryopreservation 2 (4.3 %) 0 (0 %) p= 0.516
Therapy-induced amenorrhea 17 (37.0 %) 23 (76.7 %) p= 0.002
Restored menses after treatment 14 (82.4 %) 10 (43.5 %) p= 0.012
Secondary amenorrheab 3 (6.5 %) 13 (43.3 %) p= 0.003
All pregnancies after treatment/in vitro fertilizationa 21/1 (4.8 %) 10/0 (0 %) p= 0.630
Number of patients attempting conception post-treatment 42 (91.3 %) 26 (86.7 %) p= 0.879
Number of patients having children after treatmentc 19 (45.2 %) 9 (34.6 %) p= 0.573
Menopausal problems/mean score 17 (37 %)/4.65 17 (56.7 %)/6.05 p= 0.095
Italic values indicate statistical significance
A without constitutional symptoms, B with constitutional symptoms, X bulky disease, E extranodal involvement, CR complete remission, PR partial
remission, NA not applicable, e escalated, b basal
a Number of in vitro fertilized pregnancies among all pregnancies after chemotherapy
b Percentage of all patients in ABVD and BEACOPP groups
c Percentage of patients attempting conception post-treatment
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presence of menopausal symptoms (p=0.095) or severity of
these symptoms (p=0.657). In the BEACOPP subgroups,
there was no significant difference in any of the aforemen-
tioned parameters (Table 2). When comparing the ABVD
group and the escalated BEACOPP group, a statistically sig-
nificant difference was discovered in the number of children
born before treatment began (p = 0.027) (higher in the
eBEACOPP group), in therapy-induced amenorrhea
(p<0.001) (more frequent in the eBEACOPP group), and so
was the incidence of restored menses after treatment
(p= 0.032) (less often in the eBEACOPP group). Other
parameters were considered insignificant.
Male survivors
In the ABVD group, the median age at the time of treatment
was 28 (range 20–39) (Table 3). Four (14.8 %) patients had
stage I and 23 (85.2 %) patients had stage II of the disease. Six
(22.2 %) patients had bulky disease and 3 (11.1 %) suffered
from constitutional symptoms. One (3.7 %) had extranodal
involvement. The median number of chemotherapy cycles
was 4 (range 1–6). Only three (11.1 %) patients had CR after
first line chemotherapy, while 24 (88.9 %) patients needed
additional radiotherapy. One (3.7 %) patient received irradia-
tion of the scrotum with 24 Gy due to the involvement of
regional lymph nodes while sperm cryoconservation was not
done due to his age (38 years). Three (11.1 %) patients re-
lapsed, two of them received salvage chemotherapy and are
now in remission, the third declined chemotherapy and is still
under observation without any further treatment. Thirteen
(48.1 %) patients reported male aging symptoms. Six out of
eight patients who declined sperm cryopreservation had al-
ready had children previously and were older than 35 years
of age. Only in one patient, the usage of cryopreserved sperm
was reported unsuccessful in terms of conception, other six
utilizations were successful.
In the BEACOPP group, the median age at the time of
treatment was 25.5 (range 16–38). Two (10.0 %) patients
had stage I of the disease, one (5.0 %) patient had stage II,
seven (35.0 %) patients had stage III, and ten (50.0 %) patients
had stage IV of the disease. Nine (45.0 %) patients suffered
from constitutional symptoms, nine (45.0 %) had bulky dis-
ease, and two (10.0 %) had extranodal involvement. The me-
dian number of chemotherapy cycles was 8 (range 4–8). None
of the patients were irradiated in the scrotal area. Eleven
(55.0 %) patients achieved CR after chemotherapy, nine
(45.0 %) needed radiotherapy. One (5.0 %) patient relapsed
and received salvage treatment and is now in CR. Ten (50 %)
patients reported aging male symptoms.
None of themale participants specifically stated that they did
not try to have children after chemotherapy with the exception
of the ten (eight in the ABVD and two in the BEACOPP group)
patients who refused the sperm cryopreservation. A higher age
correlated negatively with sperm cryoconservation (Table 4)
and with achieving pregnancy following chemotherapy and
correlated positively with the number of children born before
chemotherapy (p<0.001, p<0.001, p=0.010, respectively). A
higher age, however, did not correlate with the presence of
aging male symptoms (p=0.382), the severity of these prob-
lems (p=0.200), with a higher number of in vitro fertilization
procedures necessary to achieve pregnancy (p=0.826) or with
a lower number of children born following chemotherapy













Number of children before treatment p< 0.001a p = 0.002a p < 0.001a p= 0.297b p= 0.027b p= 0.168b
Therapy-induced amenorrhea p= 0.016c p = 0.118c p = 0.029c p= 0.002d p< 0.001d p= 0.712d
Restored menses after treatment p= 0.062c p = 0.348c p = 0.010c p= 0.012d p= 0.032d p= 1.000d
Secondary amenorrhea p= 0.062c p = 0.348c p = 0.010c p= 0.003d p= 0.494d p= 1.000d
Pregnancies after therapy p= 0.014c p = 0.095c p = 0.051c p= 0.630d p= 0.174d p= 0.425d
Children after therapy (yes/no) p= 0.010c p = 0.079c p = 0.040c p= 0.070d p= 0.155d p= 0.225d
Number of children after therapy p= 0.032a p = 0.191a p = 0.124a p= 0.297b p= 0.122b p= 0.205b
Menopausal symptoms p< 0.001c p = 0.013c p = 0.015c p= 0.095d p= 0.984d p= 0.454d
Severity of symptoms p= 0.665e p = 0.983e p = 0.511e p= 0.657b p= 0.766b p= 0.836b
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(p=0.921). The BEACOPP group was significantly younger at
the time they answered the questionnaire (p=0.023, data not
shown) but not at the time of diagnosis of HL (p=0.054). In the
ABVD group, a higher age correlated positively with the
number of children born before chemotherapy (p<0.001) and
the presence of aging male symptoms (p=0.028), while it cor-
related negatively with sperm cryoconservation (p<0.001) and
with achieving pregnancy after therapy (p=0.043). However, it
did not correlate with the severity of aging male symptoms
(p= 0.806) or the number of children born after therapy
(p=0.129). In the BEACOPP group, a higher age correlated
only with a higher number of children before treatment
(p=0.034) and none of the other parameters.
There was no difference between the ABVD group and the
BEACOPP group in case of sperm cryopreservation, achiev-
ing pregnancy post-treatment, the number of children after
therapy or aging male symptoms and its severity (p=0.154,
p=0.753, p=0.674, p=1.000 and p=0.426, respectively). The
only statistical significance discovered was in the frequency of
cryopreserved sperm use for artificial insemination or in vitro
fertilization for the achieved pregnancies when comparing the
ABVD and BEACOPP group as well as the ABVD and the
escalated BEACOPP group (p=0.008, p=0.002, respective-
ly). The cryopreserved sperm was more frequently used for
fertilization in the BEACOPP group with 83.3 % of patients
requiring it. No other aforementioned parameters were signif-
icantly different between the two groups. No statistically sig-
nificant difference was found in comparing the regular
BEACOPP and the escalated BEACOPP groups.
Discussion
Female survivors
The patients’ age at the time of treatment correlated with the
number of children the women had had before therapy in the
joined group, as well as in both divided groups, which is
representative of the reproductive age of the female popula-
tion. Those aged between 25–29 and 30–35 years had the
highest birth rates in Slovenia in 2013 [17]. Regardless of
the regimen used, a higher age resulted in more therapy-
Table 3 Male patients’ characteristics
ABVD group BEACOPP group p value
Number of patients 27 20 (16e, 4b) NA
Median age in years at diagnosis (range) 28 (range 20–39) 25.5 (range 16–38) p= 0.054
Stage of disease prior to treatment
I 4 (14.8 %) 2a (10.0 %) NA
II 23 (85.2 %) 1a (5.0 %) NA
III 0 (0 %) 7 (35.0 %) NA
IV 0 (0 %) 10 (50.0 %) NA
A/B 24 (88.9 %)/3 (11.1 %) 11 (55.0 %)/9 (45.0 %) p= 0.016
X 6 (22.2 %) 9 (45.0 %) p= 0.122
E 1 (3.7 %) 2 (10.0 %) p= 0.563
Median number of cycles (range) 4 (1–6) 8 (4–8) NA
CR/PR after chemotherapy 3 (11.1 %)/24 (88.9 %) 11 (55.0 %)/9 (45.0 %) p= 0.003
Irradiation of the scrotum 1 (3.7 %) 0 (0 %) p= 1.000
Number of patients receiving at least 1 cycle of eBEACOPP 0 (0 %) 16 (80.0 %) NA
Number of patients with children before treatment 10 (37.0 %) 8 (40.0 %) p= 1.000
Sperm cryoconservation prior treatment 19 (70.4 %) 18 (90.0 %) p= 0.154
Number of patients achieving pregnancy after therapy/in vitro fertilizationb 10 (37.0 %)/1 (10.0 %) 6 (30.0 %)/5 (83.3 %) p= 0.753/p= 0.008
Number of patients attempting conception post-treatment 19 (70.4 %) 18 (90.0 %) p= 0.154
Number of patients having children after therapyc 10 (52.6 %) 6 (33.3 %) p= 0.554
Aging male symptoms/mean score 13 (48.1 %)/4.60 10 (50.0 %)/3.80 p= 1.000
Italic values indicate statistical significance
A without constitutional symptoms, B with constitutional symptoms, X bulky disease, E extranodal involvement, CR complete remission, PR partial
remission, NA not applicable, e escalated, b basal
a All patients with stage I and II in BEACOPP group were treated with regular-dose BEACOPP
bNumber of artificially inseminated or in vitro fertilized pregnancies among achieved pregnancies after treatment
c Percentage of patients attempting conception post-treatment
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induced amenorrhea and with the presence of menopausal
symptoms. A higher age correlated negatively with pregnancy
achieved after treatment, children born after therapy, and the
number of children born after chemotherapy. In the
BEACOPP group, a higher age positively correlated with
therapy-induced amenorrhea and with definite secondary
amenorrhea and correlated negatively with restored menses
and with the number of children born after chemotherapy.
With no difference in median age at the time of diagnosis
between the two groups, we attributed this difference to the
depleted number of follicles in older female patients and there-
fore increased susceptibility to the toxicities of chemotherapy
[11]. For the same reason, we presume that age strongly cor-
related with menopausal symptoms. The BEACOPP regimen
has often been linked to secondary amenorrhea [3, 4, 13]
especially due to the alkylating agents used [4, 5] unlike
ABVD [12, 13]. Behringer et al. strongly correlated the risk
of amenorrhea in BEACOPP patients 4 years after chemother-
apy to 30 years of age or above [13]. Our study showed the
same and the secondary amenorrhea in the BEACOPP group
was more frequent in those above 30 years of age, but this was
not so in the ABVD group (p=0.008, p=0.537, respectively,
data not shown). In their study, Behringer et al. also correlated
30-year-old BEACOPP patients with the severity of meno-
pausal problems, which has not been proven in our study.
Namely, in our study, the p value in the BEACOPP group
was 0.724 and in the escalated BEACOPP group it was
0.442 (data not shown).
Statistically, the therapy-induced amenorrhea was signifi-
cantly different among the ABVD and BEACOPP groups
(more frequent in the BEACOPP group) as was the restored
menses following treatment (more frequent in the ABVD
group). Forty-three percent of women in the BEACOPP group
and 6.5 % in the ABVD group reported secondary amenor-
rhea, which is in accordance with the literature [13]. In the
German Hodgkin Lymphoma Study Group, a study of sec-
ondary amenorrhea was reported in 51.4 % patients who re-
ceived 8 cycle dosages for escalated BEACOPP [4], whereas
in van der Kaaij’s premature ovarian failure study, 34 % of
202 women treated with alkylating chemotherapy and only
3 % of the 151 patients treated with nonalkylating chemother-
apy developed premature ovarian failure [2]. Statistically, sec-
ondary amenorrhea was significantly different between the
ABVD and BEACOPP groups, but not in the case of compar-
ing ABVD to the escalated BEACOPP. This is fascinating as
the escalated BEACOPP was expected to do more secondary
gonadal damage than other regimens [4, 7, 18]. However,
caution is required in such an interpretation as a rather small
number of women were included in the basal BEACOPP and
escalated BEACOPP group. Moreover, as in the question-
naire, we did not specifically ask whether women were taking
oral contraceptives; this fact should also be considered while
evaluating amenorrhea.
We found no difference in the pregnancy rate among the
groups: 34.6 % of women in the BEACOPP group attempting
conception post-treatment reported having children after ther-
apy along with 45.2 % in the ABVD group, respectively,
which is almost twice the number reported in Behringer’s
study [13]. However, these numbers might have been even
higher as a number of patients reported that they have not even
tried to have children and therefore they cannot knowwhether
they are infertile. Therefore, our results may perhaps be an
underestimation of the actual fertility rate as our study only
included a questionnaire without determining hormone levels,
consequently, leaving the reduced ovarian reserve unmea-
sured. Furthermore, the extent of ovarian damage due to













Number of children before treatment p= 0.010a p < 0.001a p= 0.034a p= 0.594b p= 0.782b p= 0.475b
Sperm cryopreservation p< 0.001c p < 0.001 / p= 0.154d p= 0.276d p= 1.000d
Achieving pregnancy after treatment p< 0.001c p = 0.043c p= 0.185c p= 0.753d p= 0.512d p= 0.549d
In vitro fertilization/artificial insemination p= 0.826c / / p= 0.008d p= 0.002d p= 0.333d
Number of children after therapy p= 0.921a p = 0.129a / p= 0.674b p= 0.446b p= 0.384b
Aging male symptoms p= 0.382c p = 0.028c p= 0.386c p= 1.000d p= 1.000d p= 1.410d
Severity of aging male symptoms p= 0.200e p = 0.806e p= 0.126e p= 0.426b p= 0.432b p= 0.937b
Italic values indicate statistical significance
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salvage therapy has not been separately evaluated in this
study, hypothetically contributing additionally to lower ob-
served pregnancy rates. Still, we feel obliged to report a suc-
cessful conception and a birth of a healthy child following
high-dose chemotherapy and autologous stem-cell transplan-
tation in ABVD treated woman. Nevertheless, with no differ-
ence in the pregnancy rate following chemotherapy and in
children born following therapy, we can conclude that the
BEACOPP regimen is not as toxic as previously reported [4,
7, 13], which is also consistent with the Cochrane review of
2011 reporting no differences in fertility following treatment
between the ABVD and escalated BEACOPP regimen [19].
Still, a concerning observation was that no women in the
BEACOPP group underwent embryo/oocyte cryopreservation
and only two (4.3 %) patients in the ABVD group did, which
implies that each physician should be more aware of
discussing the fertility preservation procedures with his pa-
tient prior to treatment. In the last 2 years, almost every young
patient under the age of 40 is offered a cryopreservation pro-
cedure prior to treatment.
Male survivors
In male patients, a higher age at the time of treatment corre-
lated with the number of children born before chemotherapy
in both regimens analyzed together and separately. Regardless
of the regimen used, a higher age at the time of treatment also
correlated with a less frequent sperm cryoconservation and a
smaller probability of achieving pregnancy after chemothera-
py in general. However, it is interesting that a higher age did
not correlate with the presence of aging male symptoms or
with the severity of these symptoms. The ABVD group was
the only group where a higher age correlated with more fre-
quent aging male symptomswith the median age at the time of
treatment being 2.5 years more than in the BEACOPP group.
Miwa et al. did not find a correlation between age and the
aging male symptoms score; however, their study was con-
ducted in ambulatory men and not on cancer patients under-
going treatment [20]. The presence and severity of aging male
symptoms did not differ among group analyses, which is con-
sistent with the Behringer’s study [13].
Hormone levels were not measured in our study along with
the presence of pretreatment dysspermia as in other studies
[13, 21]. Also, questions about steroid therapy after treatment
were left out of the questionnaire. However, 52.6 % of men in
the ABVD group attempting conception post-treatment and
33.3 % of men in the BEACOPP group reported having chil-
dren after chemotherapy, 10 % with cryoconservated sperm in
the ABVD group, and 83.3 % with cryoconservated sperm in
the BEACOPP group, which could be attributed to the higher
toxicity of the BEACOPP treatment. In Behringer’s study,
only 12 % of patients treated with the BEACOPP regimen
reported parenthood after 4 years; 10 % used their
cryopreserved sperm [13]. Also, the number of sperm
cryoconservation procedures was higher in our study with
70.4 % in ABVD and 90 % in BEACOPP group vs. 30 and
37 %, respectively, in Behringer’s study which could explain
patients having more children after therapy in our study [13].
The only statistically significant parameter found was the
frequency of cryoconserved sperm use for in vitro fertilization
procedures between the ABVD group and the BEACOPP as
well as in the ABVD and the escalated BEACOPP regimen.
However, as previously mentioned, Rueffer demonstrated that
70 % of patients already suffered from semen abnormality be-
fore the initiation of anticancer treatment [8]. Also, the German
Hodgkin Study Group reported 89% of patients with azoosper-
mia and 11 % with other forms of dysspermia after BEACOPP
[21]. Since our study did not include the semen analyses and its
evaluation before treatment, we cannot conclude whether or not
the dysspermia (before or after treatment) was the cause for the
statistical difference. Still, the significance in the usage of
cryopreservated sperm (more often in the BEACOPP group)
could be due to the toxicity of the BEACOPP regimen. How-
ever, the number of children born after chemotherapy did not
differ between the two groups suggesting that our male patients
were likely affected by the gonadotoxic BEACOPP, but were
still able to achieve similar rates of parenthood as in the ABVD
group by means of assisted reproduction. The stage of the dis-
ease prior to treatment, however, was significantly higher in the
escalated BEACOPP group, which was the foundation for the
selection of more aggressive treatments, but it could also mean
that the disease was more systemic, affecting the spermatogen-
esis itself. Van der Kaaji et al. showed that in early stage HL
(stages I and II), 41 % of patients have good quality sperm,
49% intermediate, and 7% of patients have poor quality sperm
(according to the World Health Organisation classification)
[22]. However, their patients did not receive the BEACOPP
treatment. The outcome of the chemotherapy, on the other hand,
was significantly better in the BEACOPP group than in the
ABVD group, indicating a higher level of effectiveness in the
BEACOPP regimen and implying the frequent dilemma of
weighing a more effective chemotherapy option against re-
duced fertility afterwards. The other possible cause for a higher
frequency of assisted reproduction procedures in the
BEACOPP group could also be found in the men’s partners.
In the questionnaire, it was not specifically noted whether the
in vitro fertilization procedure was performed due to lowermale
reproductive capacities or female reproductive capacities.
Conclusion
Although the expected frequency of secondary amenorrhea is
high, we can also report a high percentage of pregnancies
following treatment with the ABVD and BEACOPP regi-
mens: 45.2 % in the ABVD group and 34.6 % in the
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BEACOPP group, respectively, of patients attempting con-
ception post-therapy, in comparison with previous reports.
High post-therapy fatherhood rates were also observed among
male patients with 52.6 % of patients in the ABVD group of
patients attempting conception post-therapy and 33.3 % pa-
tients in the BEACOPP group, respectively, producing chil-
dren with a significantly more frequent usage of cryopre-
served sperm in the BEACOPP group. Based on our findings,
we can conclude that even intensified chemotherapy is not a
definite predictor of infertility in young HL patients.
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